Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Polycythemia Vera 3 Myeloproliferative Disorders 3 Ovarian Neoplasms 2 Thymic aplasia 1 Prostatic Neoplasms 1 Nephritis 1 Neoplasms 1 Neoplasm Metastasis 1 Immunologic Deficiency Syndromes 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Colorectal Adenocarcinoma 1 Autoimmune Diseases 1

Interventions

Prednisone 102 enzalutamide 74 Docetaxel 72 Abiraterone Acetate 67 Leuprolide 47 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45 abiraterone 37 apalutamide 28 Prednisolone 27 bicalutamide 26 Zoledronic Acid 24 pembrolizumab 22 Goserelin 22 radium Ra 223 dichloride 21 darolutamide 21 Triptorelin Pamoate 17 cabazitaxel 15 Androgen Antagonists 15 sipuleucel-T 13 luprolide acetate gel depot 12 Injections 12 Dexamethasone 12 olaparib 11 gallium 68 PSMA-11 10 Mitoxantrone 10 Pluvicto 9 Ipilimumab 9 Dutasteride 9 Cyclophosphamide 9 relugolix 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostatic Neoplasms × Phlebotomy × Clear all

NCT00133900 2009-07-28

IMMC-38

Immunicon

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡